Search Results1-9 of  9

  • MICHINORI TOGAWA ID: 9000402408096

    Articles in CiNii:1

    • <Abstract of annual report>Effect of OKY-046,a New Thromboxane A_2 Synthetase Inhibitor, on Experimental Asthma in Guinea Pigs. (1988)
  • Michinori TOGAWA ID: 9000402085607

    Articles in CiNii:1

    • <Abstract of Published Report>IPD-1151T(Suplatast Tosilate)Inhibits Interleukin(IL)-13 Release but not IL-4 Release from Basophils. (2000)
  • TOGAWA MICHINORI ID: 9000002272522

    Articles in CiNii:1

    • <Abstract of annual report>Effect of OKY-046,a New Thromboxane A_2 Synthetase Inhibitor, on Experimental Asthma in Guinea Pigs. (1988)
  • TOGAWA Michinori ID: 9000002281277

    Pharmacological Research Center, Taiho Pharmaceutical Company (2004 from CiNii)

    Articles in CiNii:3

    • IPD-1151T (Suplatast Tosilate) Inhibits Interleukin (IL)-13 Release but Not IL-4 Release From Basophils (1999)
    • <Abstract of Published Report>IPD-1151T(Suplatast Tosilate)Inhibits Interleukin(IL)-13 Release but not IL-4 Release from Basophils. (2000)
    • The Effect of a Newly Synthesized Indazole Compound, TAS-3-124, on Experimental Autoimmune Disease (2004)
  • TOGAWA Michinori ID: 9000021246671

    Department of Pharmacology, Gifu Pharmaceutical University (1988 from CiNii)

    Articles in CiNii:1

    • Antiallergic effects of mequitazine. 2. In vivo experiments. (1988)
  • Togawa Michinori ID: 9000345337779

    Clinical Development Division, Taiho Pharmaceutical Co., Ltd. (2017 from CiNii)

    Articles in CiNii:1

    • Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind,placebo-controlled, parallel-group phase III study (2017)
  • Togawa Michinori ID: 9000345337821

    Clinical Development Division, Taiho Pharmaceutical Co., Ltd. (2017 from CiNii)

    Articles in CiNii:1

    • Therapeutic effect of bilastine in Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber) (2017)
  • Togawa Michinori ID: 9000350631044

    Clinical Development Division, Taiho Pharmaceutical Co., Ltd. (2017 from CiNii)

    Articles in CiNii:1

    • Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study (2017)
  • Togawa Michinori ID: 9000377393112

    Clinical Development Division, TAIHO Pharmaceutical Co., LTD (2017 from CiNii)

    Articles in CiNii:1

    • Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial (2017)
Page Top